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Introduction: Currently there is no adequate prevention or treatment for both oral and 
gastrointestinal mucositis induced by chemotherapy and/or radiotherapy. Supportive care of 
symptoms plays a primary role during mucositis in the pediatric clinical setting. We aimed to 
get insight in the currently used feeding strategies in clinical practice in pediatric cancer patients 
with chemotherapy-induced mucositis. 
 
Methods: A prospective observational study was performed to identify feeding strategies after 
chemotherapy courses causing mucositis in almost all patients at the University Medical Center 
Groningen (UMCG), the Academic Medical Center Amsterdam (AMC) and the Princess Maxima 
Center Utrecht (PMC). Consecutive patients, aged 0-18 years, either diagnosed with B-Non 
Hodgkin Lymphoma (B-NHL) or scheduled for autologous stem cell transplantation (SCT) 
between April 2015 and September 2016 were included in this study. In addition to the 
observational study in the Netherlands, an international online questionnaire was conducted for 
pediatric oncology centers. 
 
Results: A total of 13 patients were included, after 21 chemotherapy courses. No nutritional 
support was administered after 23.8% courses, tube feeding after 19.0% of the courses, TPN in 19.0% 
of courses and 38.1% received a combination of tube feeding and TPN. The international survey 
revealed that 63.2% of the centers administered tube feeding as first choice, 31.6% administered 
only TPN as first choice and one center administered a combination as first choice. 
 
Conclusions: There is a variability in feeding strategies in the clinical practice both in the 
Netherlands as well as worldwide. This study is a basis for future studies in this important clinical 
field to develop clinical trials comparing tube feeding and TPN both in adult and pediatric 
patients. 
 
F e e d i n g  s t r a t e g i e s  i n  p e d i a t r i c  c a n c e r  p a t i e n t s  w i t h  m u c o s i t i s  
 




Mucositis is a severe side effect of both chemotherapy and radiotherapy and can be subdivided 
in oral and gastrointestinal (GI) mucositis. Patients suffering from GI mucositis have symptoms 
like pain, vomiting, diarrhea and a decreased intake, resulting in a decreased quality of life [1-3]. 
Moreover, the patients are at increased risk to develop a bacteremia or sepsis. Eventually this may 
lead to a lower chemotherapeutic dose or delay in the next chemotherapy course, possibly 
influencing survival. Currently there is no adequate prevention or treatment for both oral and 
GI mucositis. Only supportive care of symptoms plays a primary role during mucositis in the 
pediatric clinical setting [4]. During oral mucositis the mouth is painful and oral intake may be 
difficult, but in many patients the intestine is still functioning and could be used in for example 
enteral tube feeding [5]. However, during GI mucositis it is questionable if the intestine can still 
digest and absorb the nutrients during mucositis. Previous clinical studies have shown that at 
the time of mucositis the absorption of lactose is reduced, but amino acids can still be absorbed 
[6,7]. Furthermore, from animal studies we know that glucose and amino acids could still be 
absorbed if enterally administered continuously [8,9]. In contrast, lactose and fatty acids were not 
absorbed even if continuously administered enterally [10,11]. Even more, total enteral nutrition 
was not feasible and total parenteral nutrition (TPN) was superior to maintain weight in rats [12]. 
Recently it was shown that minimal enteral feeding was feasible and possibly alters recovery after 
mucositis in a rat model [13]. In general, nutritional support in pediatric cancer patients is 
challenging, there is no consistency, and both enteral nutrition and TPN have advantages and 
disadvantages [14,15]. Tube feeding is not ideally during nausea and vomiting. On the other hand, 
TPN may induce villus atrophy and mucosal permeability in the intestine [16-18]. Furthermore, 
adult patients with early initiated TPN had more infections, 26% versus 22% and a higher 
incidence of cholestasis [19]. Even more, liver dysfunction in critically ill patients developed in 
30% in TPN patients versus 18% in patients with enteral nutrition [20]. Unfortunately, no clinical 
studies have been performed concerning nutritional support during mucositis [15]. Therefore, 
clinical trials concerning feeding strategies during mucositis are needed. However, it is important 
to know the current clinical practice in order to design clinical trials. Therefore, we set up this 
research project to get insight in the currently used feeding strategies in clinical practice in 
pediatric cancer patients with chemotherapy-induced mucositis. We determined the feeding 
strategy in a multicenter observational study in the Netherlands prospectively. In addition, an 
online survey was conducted among health care professionals internationally, to get more insight 
in the diagnosis and treatment protocols of both oral and GI mucositis, and thereby determine 





MATERIALS AND METHODS 
Observational study 
Study and subjects 
A prospective observational study was performed to identify feeding strategies after 
chemotherapy courses causing mucositis in almost all patients. The study was done at the 
University Medical Center Groningen (UMCG), the Academic Medical Center Amsterdam (AMC) 
and the Princess Maxima Center Utrecht (PMC). Consecutive patients, aged 0-18 years, either 
diagnosed with B-Non Hodgkin Lymphoma (B-NHL) or scheduled for autologous stem cell 
transplantation (SCT) between April 2015 and September 2016 were included in this study. 
Patients with B-NHL were treated according to the Dutch Childhood Oncology Group (DCOG) 
treatment protocol [21-24] and were included after both COPADM1 and COPADM2 
chemotherapy course. These two courses, consisting of vincristine, methotrexate, cyclofosfamide, 
doxorubicin and prednisone, cause mucositis in almost all patients. Before stem cell 
transplantation in, for example, neuroblastoma patients the conditioning regimen consisted of 
melphalan, etoposide and carboplatin according to treatment protocol NBL-2009 from the DCOG 
[25], but other diagnoses with other conditioning regimens were also included, as shown in  
Table 1. The Medical Ethical Committee of the University Medical Center Groningen, Groningen, 
The Netherlands exempted this study for ethical review board approval, since this study observed 
the current clinical practice and data were generated by routine medical care. For the use of the 
left over material for research purposes, all patients and/or parents signed informed consent in 
general for the treatment protocol for their disease. This study was registered in the online trial 
register (number NTR5070). 
 
Study procedures 
When a patient was admitted in the UMCG, AMC or PMC for a chemotherapy course according 
to the treatment protocol of B-NHL, or for a conditioning regimen before autologous SCT, the 
patient was eligible for inclusion. During admission the following items were registered after a 
chemotherapy course daily: feeding strategy, weight, pain score, and mucositis score. For the 
study purpose nurses and doctors were instructed to score on a daily basis the severity of 
mucositis by using the National Cancer Institute Common Criteria for Adverse Events (NCI-
CTCAE) criteria for gastrointestinal mucositis [26]. During admission, when regular blood 
sampling was performed, the remaining plasma was used to measure citrulline. Citrulline is an 
amino acid, a marker for the enterocyte mass corresponding with the severity of mucositis in 
both adult and pediatric patients as well as with villus length in a mucositis animal model [10,27-
32]. Therefore, with citrulline the level of mucositis could be checked during the study period. 
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No extra blood samples were taken for study purpose only. The study ended when the patient 
was discharged from the hospital or at time of start of the next chemotherapy course. 
 
Table 1. Patient characteristics 
Characteristic  
Patients, n  13 
Chemotherapy courses, n 21 
Age, median(range) 11(1-18) 
Sex,  
  Male, n(%) 11(84.6) 
Diagnosis 
  B-NHL 
  Systemic EBV + T cell   
     lymphoproliferative disease of childhood* 
  Neuroblastoma  
  Relapse Ewing sarcoma 
  Medulloblastoma 
  Glioma 
  Relapse Hodgkin lymphoma 










Chemotherapy courses  
  COPADM1, n(%)
  COPADM2, n(%) 




Tube feeding before chemotherapy, n(%) 5(23.8)
B-NHL; B-cell Non Hodgkin Lymphoma. * Treatment according to the  
B-NHL protocol with COPADM1 and COPADM2 courses. SCT: Stem cell 





Data collection included age, sex, chemotherapy course, daily pain score (VAS score), daily 
mucositis score (NCI-CTCAE), daily registration of tube feeding and/or parenteral nutrition 
administration. The use of analgesics, the number of bacteraemias and the duration of hospital 
stay in days were looked up in the electronic patient record. Data were entered on predesigned 
standardized case report forms and later captured into an electronic database. 
 
Citrulline 
The serum citrulline was measured by using automated ion exchange column chromatography, 




Online International survey 
In addition to the observational study in the Netherlands, an online questionnaire was conducted 
for pediatric oncology centers (Supplementary methods). The survey contained questions about 
the care of oral mucositis; the assessment/diagnosis, prevention, treatment and pain management. 
Secondly, the survey contained information about GI mucositis, concerning the diagnosis, 
assessment scale, biomarker, nutritional support, prevention, treatment and the use of pre- or 
probiotics. The survey was available online via a link on the International Society of Paediatric 
Oncology (SIOP) website. The survey was also distributed via SIOP and Multinational Association 
of Supportive Care in Cancer (MASCC) mailing lists. 
 
Statistical analysis 
Statistical analysis was done using SPSS version 22.0 for Windows (SPSS Inc., Chicago, IL, USA). 
We used descriptive statistics for all values, both in the prospective observational study and in 
the international survey. All values express mean and standard deviation if parameter is normal 




Prospective observational study  
Patient characteristics 
A total of 13 patients were included, after 21 chemotherapy courses as shown in Table 1. The 
median age was 11 (1-18) years and most patients were male (84.6%). Before start of the 
chemotherapy course, 5 patients already received nutritional support which was tube feeding in 
all cases. All 5 patients with B-NHL and one patient with systemic EBV + T cell 
lymphoproliferative disease of childhood, treated according to the B-NHL protocol, were included 
after both COPADM1 and COPADM2 course. Patients scheduled for an autologous stem cell 
transplantation (SCT) were included after the conditioning regimen(n=7). Two patients received a 
second SCT and were therefore included twice, after both conditioning regimens. 
 
Feeding strategy 
In one center it was standard care to start with TPN after stem cell reinfusion in every patient, 
independent of the nutritional status, and tube feeding was only added when the patients clinical 
condition improved and they could tolerate enteral feeding. In all other patients and in the two 
other centers it was standard care to start with tube feeding in case of decreased oral intake, and 
TPN was only administered if tube feeding was not tolerated due to vomiting, abdominal 
discomfort or diarrhea. The feeding strategy was very diverse as shown in Table 2 and Figure 1. 
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No nutritional support was administered after 23.8% courses. After 19.0% of the chemotherapy 
courses only tube feeding was administered. After 19.0% of the courses only TPN was 
administered, of which three patients in the center where it was standard care to start TPN after 
stem cell reinfusion, and one based on patient preferences. The nutritional support administered 
after most courses, 38.1%, was a combination of tube feeding and TPN, of which after seven courses 
as first step tube feeding was started, and secondly TPN was added because total enteral tube 
feeding was not tolerated. After one course first TPN was started and then as second step tube 





























Figure 1. Feeding Strategy. Feeding strategy after the chemotherapy course. The bars represent the number 
of days the nutritional support was administered. Every row represents one course. 21 courses in total. After 






















Age, median (range) 13(11-15) 10.5(10-15) 13(10-18) 6(1-16) 11(1-18) 
Highest mucositis score,
   median (range) 2(1-3) 1.5(1-2) 1(1-3) 3(2-4) 3(1-4) 
Highest pain score,
   median (range) 0(0-4) 3(0-6) 2(0-8) 7(3-9) 3(0-9) 
Pain medication:  
   Paracetamol, n(%) 5(100%) 4(100%) 3(75%) 8(100%) 20(95.2%) 
   Tramadol, n(%) 4(80%) 3(75%) 1(25%) 6(75%) 14(66.7%) 
   Morphine, n(%) 1(20%) 1(25%) 2(50%) 6(75%) 10(47.6%) 
   Other, n(%) 0(0%) 1(25%) 1(25%) 4(50%) 6(28.6%) 
Vomiting, n(%) 0(0%) 1(25%) 1(25%) 3(37.5%) 5(23.8%) 
Diarrhea, n(%) 0(0%) 1(25%) 0(0%) 5(62.5%) 6(28.6%) 
Episode with fever for which 
treatment with Ceftazidim 
and/or Vancomycin, n(%) 3(60%) 1(25%) 3(75%) 7(87.5%) 14(66.7%) 
  After start of TPN 
  Before start of TPN 
  Simultaneously with start of 









Positive blood culture, 
   n(%) 2(40%) 0(0%) 1(25%) 3(37.5%) 6(28.6%) 
Hospital stay after 
chemotherapy course in days, 
   mean±SD 13.8±2.4 11±4.3 15.5±2.1 17.5±5.9 15±4.9 
Tube feeding pain score: n=3, mucositis score n=2. Tube+tpn pain score: n=7 
 
Nutritional status  
Figure 2 shows the largest bodyweight change after a chemotherapy course in percentage 
compared with the bodyweight before a chemotherapy course. As shown, in most patients 
without nutritional support or with tube feeding alone there was a decrease in bodyweight. Nine 
patients receiving either TPN or tube feeding + TPN seemed to increase in bodyweight, without 
another specific reason to declare the remarkable increase in bodyweight. This may be due to 
either overfeeding or an increase in fluids because of increased illness. 
 
Mucositis and pain score 
The median highest mucositis score after chemotherapy courses was 3 (1-4). The median highest 
pain score after chemotherapy courses, specifically abdominal pain was 3 (0-9). Furthermore, pain 
medication was administered after 20 courses (95.2%), as shown in Table 2. Proportionally the 
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most morphine was administered in the group where the 
combination of tube feeding + TPN was administered, 




Figure 3 shows the lowest plasma citrulline levels 
measured between day 5 and day 13 after the chemotherapy 
course. Most patients receiving TPN or tube feeding+TPN 
had a lowest citrulline level below 10 umol/l, reflecting 




The patients developed fever and were consequently 
treated with Ceftazidim and/or Vancomycin after 14 
(66.7%) chemotherapy courses, as shown in Table 2. Patients 
with TPN had more episodes of fever with antibiotic 
treatment (n=10) versus patients without TPN (n=4), but 
only slightly more positive blood cultures (n=4 versus n=2, 
respectively). The episodes of fever developed after start of 
TPN in seven patients, in two patients before the start of 
TPN and in one patient simultaneously with the start of 
TPN. Furthermore, patients receiving TPN were 
hospitalized for more days after the chemotherapy course 
compared to patients without TPN (mean16.8±4.9 versus 
12.6±3.8.days). 
Online international survey 
Twenty health care professionals specialized in mucositis 
care in pediatric cancer patients completed the online 
survey. Most professionals were pediatric oncologists 
(n=15), two nurses, two pharmacists in pediatric oncology 
and one radiation oncologist. Most were working in a 
pediatric oncology department in Europe (n=13), three in 
































Figure 2. Bodyweight change. 
Largest bodyweight change in days 
after chemotherapy course, in per-
centage compared to bodyweight 
prior to chemotherapy. Between 
day 1 and day 11. The line is the 
median. Dots represent individuals 




























Figure 3. Plasma citrulline. Lowest 
plasma citrulline measured in the 
days after chemotherapy treatment. 
Each dots represent individuals 
after chemotherapy treatment.  
Line is the median per feeding 
strategy. All samples were measured 





Assessment scale to diagnose oral mucositis 
To diagnose oral mucositis 15/20 of the hospi-
tals used an assessment scale, mostly the NCI-
CTCAE (33.3%), WHO scoring scale (33.3%), 
ChIMES self scoring scale (13.3%), one combines 
the NCI-CTCAE and the WHO scale (6.7%), and 
two hospitals use their own developed scoring 
scale (13.3%). 
 
Pain medication during oral mucositis 
Mostly used pain medication during oral 
mucositis is morphine (85%), paracetamol (55%), 
tramadol (40%), topical pain medication like 
mouthwash containing lidocaine (25%) and a 
minority also uses NSAIDs (10%) as analgesia 
during oral mucositis. 
 
Prevention and treatment of oral mucositis 
The most prevalent intervention as prevention 
is mouthwash (50%) and oral cryotherapy (20%). 
In 7/20 centers (35%) no prevention is given. For 
treatment of oral mucositis interventions like 
mouthwash (35%) and low level laser therapy 
(5%) are used. In 10/20 centers (50%) no inter-
vention is used as treatment. 
 
Diagnosis of gastrointestinal mucositis 
In 14/20 centers (70%) the diagnosis of GI 
mucositis is only based on clinical symptoms 
like vomiting, abdominal discomfort and 
diarrhea. Some centers (20%) combine the 
clinical symptoms with the NCI-CTCAE 
scoring scale. One center combines the clinical 
symptoms with the daily gut score. One center 
combines the clinical symptoms with the NCI-






Figure 4. Feeding strategy during mucositis. In 19 
centers worldwide. A. Survey question: what is the 
first choice of nutritional support? B. Survey 
question: Which diet is administered as tube 
feeding. C. Survey question: Is Minimal Enteral 
Feeding administered as additive to Total 
parenteral nutrition? 
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Feeding strategy during GI mucositis 
19/20 respondents answered the questions about nutritional support as shown in Figure 4. In 
13/19 centers tube feeding is administered as first choice for nutritional support during mucositis, 
and parenteral nutrition as second choice. In 3/19 centers they administer parenteral nutrition as 
first choice and tube feeding as second choice, all of these centers are located in Northern America. 
Two centers, in Spain and Macedonia, do not administer tube feeding at all, only parenteral 
nutrition. One center chooses directly for a combination of both as nutritional support. If tube 
feeding is administered, in 5/19 this is the normal standard diet. In 8/19 centers a semi-elemental 
diet is given as tube feeding. Two centers administer elemental diet. Two centers are not sure, and 
in two centers it is the decision of the dietician. If parenteral nutrition is administered, 12/19 
centers add minimal enteral feeding(MEF) via tube. Three centers administer MEF sometimes, 
and four centers do not administer MEF as additive to parenteral nutrition. 
 
Pre- or probiotics 
Four centers administer pre-or probiotics occasionally, for example Linex® or Biopron®, but the 




This is the first study addressing nutritional support during chemotherapy-induced mucositis 
and aimed to get insight in the current feeding strategy during chemotherapy-induced mucositis 
in pediatric cancer patients. Our results showed the variability in feeding strategies concerning 
tube feeding, TPN, type of diet and administration of MEF. There is no consensus between centers 
in the Netherlands or worldwide. The feeding strategy is currently dependent on patients and 
doctors preferences. 
This observational study showed that within three centers in the Netherlands there was already 
a different standard care for nutritional support during mucositis. The results showed that one 
center started TPN in all patients receiving stem cell transplantation and only added tube feeding 
after the patient improved his/her blood count and tolerated enteral feeding. In all other cases 
nutritional support was only administered in case of a decrease in bodyweight. The first choice 
in all centers was tube feeding and TPN was only added in case of intolerance of total tube feeding, 
for example due to vomiting. Although it is only an explorative study, the results may give a 
few suggestions. First the results suggest that TPN caused a better nutritional status after 
chemotherapy courses, compared to the weight loss when no nutritional support or tube feeding 
only was administered. Secondly, in contrast, the results suggest that the administration of TPN 
was associated with more episodes of fever for which antibiotic treatment was started. In most of 
these cases, fever with antibiotic treatment developed after the start of TPN. Furthermore, 




without TPN. The pain medication and citrulline levels suggested more severe mucositis in the 
patients receiving TPN. Therefore, this suggests that the patients receiving TPN were more 
severely ill, which might have contributed to the prolonged hospitalization. 
The results from the survey, although a small number of centers participated, also suggest that 
there are inter center differences in feeding strategies. Tube feeding, TPN or a combination of 
both, are all first choice as nutritional support. Furthermore, in the majority of centers minimal 
enteral feeding is added to TPN if it is feasible, however a few centers do not administer tube 
feeding at all. Moreover, the result show that also in pain management there are many differences 
between centers. 
Since this was the first study concerning feeding strategies during mucositis, we could not 
compare the results to other studies in patients with mucositis. However, in a systematic review 
concerning critically ill pediatric patients it was also concluded that there was a lack of data and 
the main conclusion was that research is urgently needed [36]. Recently, one study determined 
the difference between early and late parenteral nutrition in critically ill pediatric patients. They 
showed that late parenteral nutrition was superior, for, amongst other things, less new infections 
and a shorter duration hospital stay [37]. This is comparable to the suggestions of our results. 
Furthermore, in children undergoing allogeneic hematopoietic stem cell transplantation, not 
specifically during mucositis, enteral nutrition is suggested to be the first option and parenteral 
nutrition the second [38]. Additionally, a systematic review concerning nutritional support in 
children with cancer receiving chemotherapy, not specifically mucositis, suggested that TPN 
might be superior compared to normal food intake [39]. However, not one study compared tube 
feeding with TPN and the main conclusion was that further research is essential. 
A limitation of this study is that it was only an observational study with descriptive statistics. 
We were therefore not able to draw conclusions about the best feeding strategy during mucositis, 
both in the observational study as well as the survey. However, we aimed to show the currently 
used feeding strategies in the clinical practice in pediatric cancer patients with chemotherapy-
induced mucositis. Therefore, this study may contribute to the design of clinical trials comparing 
feeding strategies and eventually the development of guidelines to improve the clinical practice. 
In conclusion, since there are both discordances in the clinical practice in the Netherlands and 
worldwide, as well as a lack of knowledge, we are in need of a clinical trial concerning feeding 
strategies during mucositis. In the meantime, based on our results in combination with literature, 
we suggest to administer tube feeding as first choice, with an easy access to TPN in case of 
decreased nutritional status or intolerance for tube feeding. Although TPN may be effective to 
stay in a good nutritional condition, we suggest to be careful to introduce TPN as first option as 
feeding strategy since it possibly increases the risk for infection. However, further research is 
needed to draw conclusions. Therefore, this study is a basis for future studies in this important 
clinical field to develop clinical trials comparing tube feeding and TPN both in adult and pediatric 
patients. 
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1. Do you use an assessment scale to diagnose oral mucositis?  
 Yes 
 No  
 
2. (Only if yes in question 1) Which assessment scale do you use to score the severity of oral 
mucositis? 
 NCI-CTCAE scoring scale 
 WHO scale 
 ChIMES (Children’s International Mucositis Evaluation Scale) 
 OMDQ (Oral Mucositis Daily Questionnaire) 
 Other:       
 
3. Which pain medication do you use for oral mucositis (more than one answer possible)?  
 Paracetamol  
 NSAID’s (nonsteroidal anti-inflammatory drugs) 
 Tramadol  
 Morphine  
 Topical pain medication, namely:       
 Other:       
 
4. Do you use an intervention as PREVENTION for oral mucositis?  
 Oral cryotherapy 
 KGF-1/Palifermin 
 Low level laser therapy 
 Mouthwash, namely:        
 Other, namely:       
 None  
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5. Do you use an intervention as TREATMENT for oral mucositis?  
 Oral cryotherapy 
 KGF-1/Palifermin 
 Low level laser therapy 
 Mouthwash, namely:        
 Other, namely:       
 None  
 
6. If you use an intervention as prevention and/or treatment(question 4 and 5), please specify 
(when, which patients, duration, device etc): 




7. How do you diagnose GI mucositis (not including the oral cavity)?  
 Clinical diagnosis: vomiting, abdominal discomfort, diarrhea 
 Assessment scale (If yes, please specify in question 8) 
 Biomarker, namely:       
 Other:       
 
8. (Only if yes in question 7 for use of assessment scale) Which assessment scale do you use to 
score the severity of GI mucositis? 
 NCI-CTCAE scoring scale 
 Daily Gut Score  
 Other:       
 
9. What is the first choice for nutritional support during GI mucositis?  
 Tube feeding 
 Parenteral nutrition 
 Other, namely:       
 
10. What is the second option for nutritional support during GI mucositis?  
 Tube feeding 
 Parenteral nutrition 





11. When do you choose tube feeding and when parenteral nutrition? 
 Tube feeding:       
 Parenteral nutrition:       
 
12. If tube feeding is administered during GI mucositis, what kind of diet is most frequently 
administered?  
 Standard, namely:       
 Semi-elemental, namely:       
 Elemental, namely:       
 Other, namely:       
 
13. If parenteral nutrition is administered, do you administer minimal enteral feeding (10-20% 
of normal caloric intake)? 
 Yes, please specify kind of diet and amount:       
 No 
 Other, namely:       
 
14. Do you use an intervention as PREVENTION for GI mucositis?  
 Yes, namely:       
 No 
 
15. Do you use an intervention as TREATMENT for GI mucositis?  




16. Are pre- or probiotics prescribed to patients with GI mucositis?  
 Yes, namely:       
 No 
 
17. Comments:  
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